Sana Biotechnology, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $29,761 | $60,874 | $66,950 | $117,322 |
| Research and development related success payments and contingent consideration | 10,262 | (27,944) | 12,219 | 10,063 |
| General and administrative | 10,341 | 16,442 | 21,825 | 32,711 |
| Impairment of long-lived assets | 44,611 | - | 44,611 | - |
| Total operating expenses | 94,975 | 49,372 | 145,605 | 160,096 |
| Loss from operations | (94,975) | (49,372) | (145,605) | (160,096) |
| Interest income, net | 577 | 3,202 | 1,569 | 6,236 |
| Other income (expense), net | 598 | (4,121) | 847 | (3,906) |
| Net loss | $(93,800) | $(50,291) | $(143,189) | $(157,766) |
| Net loss per common share – basic and diluted | $(0.39) | $(0.21) | $(0.60) | $(0.70) |
| Weighted-average number of common shares – basic and diluted | 238,409 | 234,440 | 237,996 | 225,872 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.